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Abstract
Background: Although serogroup 20 is not part of any conjugate pneumococcal vaccine, its serotype 20A, but not
20B, belongs to the polysaccharide 23-valent formula. Little is known about its clinical, laboratorial and epidemiological
characteristics.
Methods: The purpose of this study was to evaluate the bacterial genotypes (by PFGE and MLST), clinical characteristics
of patients (from review of medical records) and antimicrobial susceptibility of serogroup 20 isolates which were
recovered from patients with invasive pneumococcal disease (IPD) from 2007 to 2012. Subtyping to determine 20A and
20B types was also performed by sequencing the genes of the cps locus.
Results: Sixteen isolates were genotyped and were highly related. All pneumococci were resistant to tetracycline and
31 % were non-susceptible to trimethoprim/sulfamethoxazole. Penicillin MIC ranged from 0.004 to 1 μg/mL and non-
susceptibility (MIC≥ 0.12 μg/mL) was observed in 5/16 isolates (31 %). All isolates belonged to subtype 20B. Most
patients were male with a median age of 62 years and presented at least one underlying disease (mostly respiratory
conditions). All isolates belonged to ST8889 and to a unique PFGE clone.
Conclusions: A high clonal occurrence of serotype 20B pneumococci recovered from patients with IPD in Brazil was
observed. As a non-PCV10 serotype, selective pressure may be responsible for this unusual occurrence of serogroup 20.
However, temporal variation effect should not be underestimated; therefore it is an issue that warrants continued
monitoring.
Keywords: Streptococcus pneumoniae, Invasive pneumococcal disease, Serogroup 20, Molecular epidemiology
Abbreviations: GHC, Grupo Hospitalar Conceição; HCPA, Hospital de Clínicas de Porto Alegre; HMD, Hospital Mãe de
Deus; ICU, Intensive care units; IPD, Invasive pneumococcal diseases; MIC, Minimal inhibitory concentration;
MLS, Multilocus sequence typing; PCR, Polymerase chain reaction; PCV, Pneumococcal conjugate vaccine; PFGE, Pulsed-
field gel electrophoresis; PPV23, Pneumococcal polyssacharyde vaccine; ST, Sequence type.
Background
To reduce the burden of pneumococcal diseases, especially
invasive cases, different vaccine formulations have been
introduced worldwide [1–6].
Serogroup 20 is part of the 23-valent polysaccharide
pneumococcal vaccine (PPV23), but it is not included in
any of the available conjugate formulations. Albeit in a
low proportion, this serotype has been found in the naso-
pharynx of children [7–12] and has also been reported as
a cause of invasive disease [13–20]. Although little is
known about specific characteristics related to its viru-
lence, this serogroup has been associated with increased
disease severity, invasiveness and mortality [15, 21]. In
addition, serogroup 20 has also been linked with some
clinically relevant resistance phenotypes, such as levoflox-
acin resistance [22].
In Brazil, serogroup 20 has recently been recognized
among the more prevalent serotypes in the post-vaccine
period [23]. Analysis of these isolates by multilocus
sequence typing (MLST) identified them as belonging to
the same (and newly described) sequence type (ST)
8889. Cálix and co-workers (2012) [24] subtyped isolates
* Correspondence: julianaca@ufcspa.edu.br
1Basic Health Department, Federal University of Health Science of Porto
Alegre, Porto Alegre, Brazil
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Caierão et al. BMC Infectious Diseases  (2016) 16:418 
DOI 10.1186/s12879-016-1773-y
belonging to serogroup 20 based on differences in the
cps locus and designated these variants as 20A and 20B.
They showed distinguishable antigenicity when human
sera from patients who were vaccinated with the PPV23
were used. The authors concluded that this vaccine con-
tains serotype 20A polysaccharide, but not 20B.
Compared with other serotypes, there is a restricted
number of strains of serogroup 20 described in the MLST
database (http://pubmlst.org/spneumoniae/) and therefore
additional molecular epidemiology analyses remain to be
explored. The aim of this work was to characterize isolates
of serogroup 20 recovered from patients with IPD in Porto
Alegre, South Brazil.
Methods
Study setting and bacterial isolates
S. pneumoniae isolates from patients with IPD have been
systematically collected as part of our surveillance studies.
From January 2007 to December 2012, 358 pneumococci
were recovered from patients attending three hospitals in
Porto Alegre, Brazil: Hospital Mãe de Deus (HMD), Grupo
Hospitalar Conceição (GHC) and Hospital de Clínicas de
Porto Alegre (HCPA). One isolate per patient was consid-
ered. Identification was confirmed by optochin susceptibil-
ity and bile solubility tests [25]. Serotyping was performed
for 336 isolates by multiplex PCR [26] and/or Quellung
reaction. Among all S. pneumoniae, 4.8 % (16/336) were
identified as serogroup 20 and included in the present
study. Isolates were stored in Skim Milk® (Difco) with 5 %
glycerol at -80 °C.
Antimicrobial susceptibility tests
Minimal inhibitory concentration (MIC) to the following
antimicrobials was determined by broth microdilution, as
recommended by CLSI, 2013 [27]: penicillin, ceftriaxone,
erythromycin, tetracycline, trimethoprim/sulfamethoxa-
zole, levofloxacin, chloramphenicol and vancomycin. The
reference strain S. pneumoniae ATCC 49619 was used for
quality control.
Genetic characterization of serogroup 20 cps locus
Regions of the capsular genes that previously demon-
strated genetic variability between serotypes 20A and
20B [28] were sequenced: wcjE, wchA and whaF.
DNA extraction was performed using a 5 % suspen-
sion of Chelex® 100 resin (Biorad). The oligonucleo-
tide sequences used were designed based on the
nucleotide sequence of the published serogroup 20
cps locus (GenBank™ accession number CR931679.1)
and are shown in Table 1. PCR reaction included
1.2 μM of each primer, 2.5U of Taq DNA polymerase
and 3.5 mM of MgCl2. Reaction conditions included
an initial denaturation at 94 °C for 4 min, 30 cycles
of denaturation (94 °C for 45 s), annealing (56 °C for 45 s)
and extension (72 °C for 2.5 min) and a final extension at
72 °C for 5 min. PCR products were purified with
ExoSAP-IT (Affymetrix USB, Santa Clara, CA) and cycle
sequenced using the BigDye Terminator V3.1 chemistry
(Life Technologies, Carlsbad, CA). Sequencing reactions
were analyzed on an ABI 3130xl genetic analyzer (Applied
Biosystems, Carlsbad, California, USA).
Molecular typing
Pulsed-field gel electrophoresis (PFGE) and MLST
techniques were used for molecular typing. PFGE was
performed according to McEllistrem et al. (2000) [28]
and Pinto et al. (2013) [29]. PFGE patterns were clus-
tered by UPGMA. A dendrogram was generated from
a similarity matrix calculated using the Dice similarity
coefficient with an optimization of 0.5 % and a toler-
ance of 1.5 %. A non-invasive serogroup 20 isolate
(079-12), recovered during the same period from a
sputum sample, was included for comparative pur-
poses. Clonal relationship among isolates was defined
according to parameters published by Tenover and
co-workers (1995) [30].
MLST was previously performed by our group [23],
according to Enright & Spratt (1998) [31], using modified
primers described at CDC’s Streptococcus Laboratory web-
site (http://www.cdc.gov/streplab/alt-mlst-primers.html).
Analysis of medical records
Patient’s records were evaluated to obtain information
such as age, gender, intensive care unit (ICU) admis-
sion, outcome and occurrence of the following under-
lying conditions: diabetes, hypertension, HIV infection,
Table 1 Primers sequences used for PCR and sequencing
Region Sequence Amplicon (bp) Reference
wcjE 5’-AGCCTTACTATCCGATCAACG-3’ 1334 Calix et al, 2012 [24]
5’-CTTGTTATGACGCGCTTACC-3’ Calix et al, 2012 [24]
wchA 5’-CCTGTTACTTGCGAACGATG-3’ 374 Calix et al, 2012 [24]
5’-GACCAACGATAGCTCCACAAA-3’ This article
whaF 5’- TGAATTTGAAGAGATAAGGGAAA-3’ 457 This article
5’-CCCGTGTTACATAAGGTGTTG-3’ This article
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liver diseases, chronic kidney failures, asplenia, chronic
obstructive pulmonary disease, autoimmune disease,
transplantation, neoplasia, smoking and alcoholism.
Ethical considerations
This retrospective study was approved by the Research
Ethical Committee of Grupo Hospitalar Conceição (Project
number 11-205). Patient records and information were
anonymized and de-identified prior to analysis.
Results and discussion
From 2007 to 2012, 16 out of 336 pneumococci recovered
from patients with IPD belonged to serogroup 20. Yildirim
and co-workers (2012) [17] evaluated prevalence of sero-
types causing invasive diseases in two periods: directly after
PCV7 implementation in USA (2000-2002) and a few years
later (2009-10) and also observed an increase in the pro-
portion of invasive disease caused by serogroup 20. How-
ever, other studies have reported a stable participation of
this serogroup in invasive disease over the years [15].
Yearly, the proportion of serogroup 20 increased
from 2007 (1/43, 2 % were serotype 20) to 2011 (with
11/125, 9 % of all pneumococci serotyped as 20) and
decreased after that (1/76, 1 % in 2012). Indeed, most
of the cases of invasive disease caused by serogroup 20
were detected after the implementation of PCV10
(69 %; 11/16), mainly in the year 2011. However, such
effect of the vaccine would be unlikely only one year
after the beginning of the vaccination program,
especially among adults, and in addition only one ser-
ogroup 20 case was observed in 2012. It is well known
that temporal variations in the distribution of pneumo-
coccal serotypes are expected, independent of selective
pressure due to antibiotic use or vaccination and is a
more likely explanation for the changes in prevalence
seen in this study than is vaccine-related serotype re-
placement [32].
Most patients were male (56 %; 9/16). For two pa-
tients, no gender data were available. The age of patients
varied from 37 to 85 years old and the average and me-
dian ages were 61.6 and 62 years old, respectively. Eight
(50 %) patients were ≥65 years old. Most isolates were
recovered from patients admitted at GHC (81 %; 13/16).
Isolates from HCPA and HMD represented 12 % (2/16)
and 6 % (1/16), respectively.
The majority of isolates (87 %; 14/16) were from
blood and the remainder from cerebrospinal fluid
(CSF). Although some authors have reported both in-
vasive [13, 33] and non-invasive [20] infections caused
by pneumococci from serogroup 20 in adults, studies
consistently describe this serogroup in invasive disease
among children [15, 17, 19, 36]. Most studies report
serogroup 20 associated with bacteremia and/or men-
ingitis [21, 34]. Also, serogroup 20 appears to be
found in a very small proportion of pneumococci in
the nasopharynx of children [7–12].
Medical records were available for 12 patients (Table 2).
All of them presented at least one underlying condition.
Table 2 Clinical manifestations of patients presenting with invasive disease caused by serogroup 20 S. pneumoniae isolates
ID# Datea Origin Source Age DM SAH HIV Liver disease COPD Neoplasia Smoking Alcoholism ICU Death
009–07 pre GHC blood NA NA NA NA NA NA NA NA NA NA NA
044–09 pre GHC blood NA NA NA NA NA NA NA NA NA NA NA
045–09 pre GHC blood 85–89 no yes no no no no no no no no
079–09 pre GHC CSF 55–59 no yes no no yes no yes yes no no
014–11 pre GHC blood 70–74 yes no no no no yes no no no no
056–11 post GHC blood 50–54 no no yes no no no no no no no
089–11 post HCPA blood NA NA NA NA NA NA NA NA NA NA NA
103–11 post HCPA CSF NA NA NA NA NA NA NA NA NA NA NA
114–11 post GHC blood 70–74 yes yes no no yes no yes no no no
121–11 post GHC blood 65–69 no yes no no yes no No no no no
124–11 post GHC blood 65–69 no no no yes yes no yes yes yes yes
130–11 post GHC blood 35–39 no no no no no no yes yes yes no
136–11 post GHC blood 65–69 no no no no no yes yes no no no
142–11 post GHC blood 75–79 no no no no no yes no no no yes
161–11 post HMD blood 50–54 no no no no no no no no no no
031–12 post GHC blood 80–84 yes yes no no no no no no no no
aDate is referred to periods pre-vaccination (from 2007 to 2010) and post-vaccination (from 2010 to 2012)
GHC Grupo Hospitalar Conceição, HCPA Hospital de Clínicas de Porto Alegre, HMD Hospital Mãe de Deus, NA not available, DM diabetes mellitus, SAH systemic
arterial hypertension, COPD chronic obstructive pulmonary disease, ICU admission to intensive care unit
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The most common underlying conditions were chronic
obstructive pulmonary disease (COPD) (4/12; 33 %), alco-
holism (4/12; 33 %), systemic arterial hypertension (5/12;
42 %) and smoking (5/12; 42 %). Indeed, it is well-
established that pneumococcal diseases (considering all
serotypes) are facilitated by abnormal conditions of the
respiratory tract or underlying conditions [6]. Three
patients (25 %) needed admission to ICU.
Five of the 12 (42 %) patients with known outcome
died. However, it is difficult to established mortality
attributable to pneumococcal infection as underlying
conditions were a common feature. Despite these
confounders, some studies have demonstrated an in-
creased risk of invasive disease and/or poor outcome
related to serogroup 20. In this context, Grabenstein
and co-workers (2014) [33] performed a systematic
review to characterize differences in serious outcome
between pneumococcal serotypes; among seven adult
studies evaluating meningitis, serogroup 20 was
among the group with elevated risk. Also, Jansen and
co-workers (2009) [13] demonstrated that serogroup
20 was among the serotypes that caused meningitis
and bacteremia without focus in a relatively high pro-
portion compared to other serotypes. Other studies
focusing on analysis of invasiveness demonstrate that
this serogroup, along with others, was found to have
an enhanced propensity to cause invasive disease [21].
Despite this important characteristic of invasiveness,
serogroup 20 was associated with low rates of case-
fatality [13]. In contrast, eight deaths among 569 IPD
cases reported by Hsu and co-workers (2010) [15]
were associated with a group of non-PCV7 isolates,
including serogroup 20.
All pneumococci were resistant to tetracycline and
31 % (5/16) were non-susceptible to trimethoprim/
sulfamethoxazole (2 with intermediate resistance and
3 fully resistant). Interestingly, we had previously
characterized the antimicrobial susceptibility profile of
159 pneumococci recovered from invasive disease in
our region [35] and resistance to tetracycline was ob-
served in 22 % of the isolates. Penicillin MICs ranged
from 0.004 to 1 μg/mL and resistance (MIC ≥
0.12 μg/mL) was observed in 31 % (5/16) MIC50 for
penicillin was very low (<0.03 μg/mL); MIC90 was
0.5 μg/mL and one isolate had an MIC of 1.0 μg/mL.
Among the limited number of available studies
describing antimicrobial susceptibility profiles of ser-
ogroup 20 isolates, non-susceptibility to penicillin was
not observed by Dunais et al (2011) [7], while one
paper reported MICs higher than 0.12 μg/mL [36].
Our isolates were susceptible to all other antimicro-
bials tested. Indeed, as described in literature, resist-
ance to other antimicrobials appears to be low.
Rudolph and co-workers (2013) [37] found a very
small proportion of isolates of serogroup 20 non-
susceptible to erythromycin among invasive pneumo-
cocci recovered from Alaska (1986–2010). Recently,
Guo and co-workers (2014) [22] reported two
pneumococci belonging to serotype 20B presenting
resistance to quinolones in China.
All but one isolate (121–11) were previously sub-
mitted to the MLST website; all isolates represented a
unique and newly described sequence type: ST8889
[23]. Rudolph and co-workers (2013) [37] typed an
erythromycin non-susceptible serogroup 20 isolate
and found it to be ST1030, which is one of the 95
serogroup 20 sequence types listed at the MLST web-
site. These STs are distributed in 12 groups (with 59
STs) and 35 singletons. ST 8889 is part of the major
clonal complex (CC235) and is a single locus variant
of the ancestor, ST235 (Fig. 1).
PFGE grouped all the 16 invasive isolates in a single
clone (similarity of 80 % or more in the band pattern).
Most isolates (87 %; 14/16) had an identical band pro-
file, and the remaining two pneumococci (044–99 and
045–99) presented a very similar band pattern (Fig. 2).
The two isolates recovered from CSF were included in
the major PFGE band profile and the ones recovered
from patients attending different hospitals (HMD and
HCPA) also presented the major band profile. Interest-
ingly, the non-invasive isolate (079–12) included for
comparison purposes presented the most distinct band
pattern, as shown in Fig. 1, and it was not included in
the same clone.
According to Calix and co-workers (2012) [24], sero-
type 20B (GenBank™ accession number JQ653093.1) is
identical to the reference strain of serogroup 20 (Gen-
Bank™ accession number CR931679.1), except for the
occurrence of a silent mutation in wcjE (936 c::t). On
the other hand, serotype 20A (GenBank™ accession
number JQ653094.1) presents three alterations in genes
of the cps locus: mutation in wchA (659 t::g), mutation
in whaF (898 a::c) and an adenosine insertion within a
polyadenosine tract in whaF (position 881). None of
the 16 pneumococci had these alterations. The wchaA
gene of our isolates was identical to the strains
CR931679.1 and JQ653093.1 (20B), as well as for whaF.
The wcjE gene of isolates included in this study did not
have the 936 c::t mutation observed in 20B
(JQ653093.1). However, as this is a silent mutation, we
can deduce that the protein constitution of our isolates
is the same as the previously described 20B. Serotype
20B seems to be the more common subtype identified
amongst serogroup 20 isolates, at least among the re-
stricted number of serogroup 20 isolates subtyped so
far. Our subtyping results correlated with Calix et al
(2012) [24] who identified serotype 20B amongst their
isolates, which were also all from IPD.PPV23 includes



















Fig. 2 Representative dendogram of the invasive serogroup 20 pneumococci generated by PFGE. A non-invasive isolate belonging to serogroup
20 (079-12) was included for molecular epidemiology comparison, only
Fig. 1 Population snapshot of 151 serogroup 20 isolates in the S.pneumoniae MLST database (accessed in April 2015) based on eBURST analysis.
Each ST encountered is indicated by a circle, with their diameters being proportional to the numbers of isolates. ST described by our group [23]
is highlighted in red
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serotype 20A and although Calix and co-workers [24]
infer there might be effective cross-protection against
20B, they suggest epidemiological analyses are war-
ranted to confirm these data.
Conclusions
Serogroup 20 is an infrequent non-PCV serotype and little
is known about its molecular epidemiology and clinical
disease presentation. As changes in the pneumococcal
population are expected due to temporal variation and/or
selective pressure of vaccination/antimicrobial use, it is
important to generate data to better understand the evolu-
tion of serotypes not included in available conjugate vac-
cine formulations. As far as we know, this is the first study
devoted to this serotype in Latin America. We focused on
the occurrence of a specific ST of serotype 20B, a serotype
not included neither in the conjugate nor polysaccharide
vaccines. This observation leads to the need of further
surveillance for this non-vaccine serotype.
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